Matches in SemOpenAlex for { <https://semopenalex.org/work/W2493634706> ?p ?o ?g. }
- W2493634706 abstract "There have been a number of studies with conflicting results which have examined the effect of anti-tuberculous therapy in Crohn's disease. A meta-analysis was performed to evaluate the use of anti-tuberculous therapy for the maintenance of remission in Crohn's disease.To evaluate the effects of anti-tuberculous therapy for the maintenance of remission in patients with Crohn's disease.We searched MEDLINE, EMBASE, the Cochrane LIbrary, and the Cochrane IBD Group Specialized Register from inception to June 22, 2015.Randomized controlled trials (RCTs) of anti-tuberculous therapy compared to placebo or another active therapy in patients with quiescent Crohn's disease were considered for inclusion.At least two authors independently extracted data and assessed the quality of included studies using the Cochrane risk of bias tool. We calculated the risk ratio (RR) and corresponding 95% confidence interval (CI) for dichotomous outcomes.. The primary outcome was relapse. Secondary outcomes included adverse events, withdrawals due to adverse events and serious adverse events. All data were analyzed on an intention-to-treat basis. The overall quality of the evidence supporting the primary and secondary outcomes was evaluated using the GRADE criteria.Four placebo-controlled RCTs including 206 participants were included. Three trials included an 8 to 16 week induction phase with tapering corticosteroids (prednisone, prednisolone or methylprednisolone) as induction therapy. Anti-tuberculous therapy included monotherapy with clofazimine, combination therapy with clofazimine, rifampin, ethambutol, and dapsone or combination therapy with clarithromycin, rifabutin and clofazimine. All of the studies were rated as unclear risk of bias for allocation concealment, three were rated as unclear risk of bias for random sequence generation and two were rated as unclear risk of bias for blinding or participants and personnel. There was a statistically significant difference in relapse rates favoring anti-tuberculous therapy over placebo. Thirty-nine per cent (44/112) of patients in the anti-tuberculous therapy group relapsed at 9 months to 2 years compared to 67% (63/94) of placebo patients (RR 0.58, 95% CI 0.45 to 0.75, I(2) = 47%). A GRADE analysis indicates that the overall quality of the evidence supporting this outcome was very low due to unknown risk of bias and sparse data. Adverse events occurred more frequently in the anti-tuberculous therapy group (37/159) compared to the placebo group (14/163) with a pooled RR of 2.57 (95% CI 1.45 to 4.55; N=322; studies=4, I(2)=64%). A GRADE analysis indicates that the overall quality of the evidence supporting this outcome was very low due to unknown risk of bias, unexplained heterogeneity and sparse data. There was no difference in withdrawals due to adverse events. Nine per cent (14/159) of anti-tuberculous therapy patients withdrew due to adverse events compared to 7% (11/163) of placebo patients (RR 1.29, 95% CI 0.60 to 2.77, I(2) = 0%). Common adverse events included increased skin pigmentation and rashes. No serious adverse events were reported in any of the included studies.Anti-tuberculous therapy may provide a benefit over placebo for the prevention of relapse in participants with Crohn's disease in remission. However, this result is very uncertain due to unclear study quality and the small numbers of patients assessed. Further studies are needed to provide better quality evidence for the use of anti-tuberculous therapy for maintaining remission in people with quiescent Crohn's disease." @default.
- W2493634706 created "2016-08-23" @default.
- W2493634706 creator A5015307273 @default.
- W2493634706 creator A5036883744 @default.
- W2493634706 creator A5055840412 @default.
- W2493634706 creator A5065846093 @default.
- W2493634706 date "2016-07-22" @default.
- W2493634706 modified "2023-10-14" @default.
- W2493634706 title "Anti-tuberculous therapy for maintenance of remission in Crohn's disease" @default.
- W2493634706 cites W1954061514 @default.
- W2493634706 cites W1970050611 @default.
- W2493634706 cites W1971473890 @default.
- W2493634706 cites W1980660341 @default.
- W2493634706 cites W1995417009 @default.
- W2493634706 cites W2002099481 @default.
- W2493634706 cites W2014358676 @default.
- W2493634706 cites W2029107507 @default.
- W2493634706 cites W2053497755 @default.
- W2493634706 cites W2059019883 @default.
- W2493634706 cites W2079529102 @default.
- W2493634706 cites W2087176461 @default.
- W2493634706 cites W2117537840 @default.
- W2493634706 cites W2120192049 @default.
- W2493634706 cites W2128474861 @default.
- W2493634706 cites W2133224803 @default.
- W2493634706 cites W2138642538 @default.
- W2493634706 cites W2158630793 @default.
- W2493634706 cites W2165010366 @default.
- W2493634706 cites W2222297951 @default.
- W2493634706 cites W2316668520 @default.
- W2493634706 cites W2332160220 @default.
- W2493634706 cites W2340491704 @default.
- W2493634706 doi "https://doi.org/10.1002/14651858.cd000299.pub3" @default.
- W2493634706 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6457855" @default.
- W2493634706 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27444319" @default.
- W2493634706 hasPublicationYear "2016" @default.
- W2493634706 type Work @default.
- W2493634706 sameAs 2493634706 @default.
- W2493634706 citedByCount "10" @default.
- W2493634706 countsByYear W24936347062018 @default.
- W2493634706 countsByYear W24936347062019 @default.
- W2493634706 countsByYear W24936347062020 @default.
- W2493634706 countsByYear W24936347062021 @default.
- W2493634706 countsByYear W24936347062022 @default.
- W2493634706 countsByYear W24936347062023 @default.
- W2493634706 crossrefType "journal-article" @default.
- W2493634706 hasAuthorship W2493634706A5015307273 @default.
- W2493634706 hasAuthorship W2493634706A5036883744 @default.
- W2493634706 hasAuthorship W2493634706A5055840412 @default.
- W2493634706 hasAuthorship W2493634706A5065846093 @default.
- W2493634706 hasBestOaLocation W24936347062 @default.
- W2493634706 hasConcept C126322002 @default.
- W2493634706 hasConcept C141071460 @default.
- W2493634706 hasConcept C142724271 @default.
- W2493634706 hasConcept C168563851 @default.
- W2493634706 hasConcept C197934379 @default.
- W2493634706 hasConcept C203014093 @default.
- W2493634706 hasConcept C204787440 @default.
- W2493634706 hasConcept C27081682 @default.
- W2493634706 hasConcept C2776297342 @default.
- W2493634706 hasConcept C2776409635 @default.
- W2493634706 hasConcept C2776694085 @default.
- W2493634706 hasConcept C2776760755 @default.
- W2493634706 hasConcept C2776962512 @default.
- W2493634706 hasConcept C2778283404 @default.
- W2493634706 hasConcept C2778720950 @default.
- W2493634706 hasConcept C2779134260 @default.
- W2493634706 hasConcept C2779280984 @default.
- W2493634706 hasConcept C2780695269 @default.
- W2493634706 hasConcept C71924100 @default.
- W2493634706 hasConceptScore W2493634706C126322002 @default.
- W2493634706 hasConceptScore W2493634706C141071460 @default.
- W2493634706 hasConceptScore W2493634706C142724271 @default.
- W2493634706 hasConceptScore W2493634706C168563851 @default.
- W2493634706 hasConceptScore W2493634706C197934379 @default.
- W2493634706 hasConceptScore W2493634706C203014093 @default.
- W2493634706 hasConceptScore W2493634706C204787440 @default.
- W2493634706 hasConceptScore W2493634706C27081682 @default.
- W2493634706 hasConceptScore W2493634706C2776297342 @default.
- W2493634706 hasConceptScore W2493634706C2776409635 @default.
- W2493634706 hasConceptScore W2493634706C2776694085 @default.
- W2493634706 hasConceptScore W2493634706C2776760755 @default.
- W2493634706 hasConceptScore W2493634706C2776962512 @default.
- W2493634706 hasConceptScore W2493634706C2778283404 @default.
- W2493634706 hasConceptScore W2493634706C2778720950 @default.
- W2493634706 hasConceptScore W2493634706C2779134260 @default.
- W2493634706 hasConceptScore W2493634706C2779280984 @default.
- W2493634706 hasConceptScore W2493634706C2780695269 @default.
- W2493634706 hasConceptScore W2493634706C71924100 @default.
- W2493634706 hasIssue "7" @default.
- W2493634706 hasLocation W24936347061 @default.
- W2493634706 hasLocation W24936347062 @default.
- W2493634706 hasLocation W24936347063 @default.
- W2493634706 hasLocation W24936347064 @default.
- W2493634706 hasOpenAccess W2493634706 @default.
- W2493634706 hasPrimaryLocation W24936347061 @default.
- W2493634706 hasRelatedWork W1522944862 @default.
- W2493634706 hasRelatedWork W1875330998 @default.
- W2493634706 hasRelatedWork W2043744703 @default.
- W2493634706 hasRelatedWork W2075583371 @default.